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Abstract
Background: Most available data indicates that stenting for unprotected left main coronary
artery disease (ULMCA) with drug-eluting stents (DES) is safe and effective. At present,
surgery is considered the gold standard for optimal revascularization. The aim of this study
was to evaluate the immediate and long term outcome of patients with ULMCA stenosis who
underwent percutaneous coronary intervention (PCI) with DES implantation in a single
center.
Methods: Coronary stents were implanted into ULMCA in 72 patients. Patients with a de
novo ≥ 50% diameter stenosis, or £ 4.0 mm2 on intravascular ultrasound measurement of
left main coronary artery were treated using 1.6 ± 1.2 DES per patient. ULM stenting was
performed when coronary artery bypass grafting was considered at high surgical risk (mean
EuroSCORE 7.1) and/or surgery was refused despite their physician’s recommendation. Pa-
tients enrolled in the study underwent clinical evaluation one, six and 12 months after the pro-
cedure, and then annually. Coronary angiography was routinely performed at nine to 12 months
from the index procedure and/or was clinically driven at any time. Acute and long term main
adverse cardiac events (MACE) were assessed: cardiac death, myocardial infarction and
additional target lesion or non-target lesion revascularization (TLR).
Results: Angiographic and clinical success of PCI was 100%. Complete revascularization
was performed in all patients. Mean follow-up duration was 2.5 years ± 10 months with 3%
mortality in the first 12 months and total MACEs in 30.6%. During follow-up, death occurred
in four (5.5%) patients. Angiographic follow-up was performed in 59 (82%) patients and TLR
occurred in 18.05% of treated lesions. One possible stent thrombosis was documented.
Conclusions: Considering the high surgical risk present in most of our patients, ULM
stenting is feasible and safe with excellent immediate and mid-term results. Long term results
seem to be encouraging, showing limited mortality and the total absence of definite or probable
thrombosis. (Cardiol J 2011; 18, 2: 165–170).
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166
Cardiology Journal 2011, Vol. 18, No. 2
www.cardiologyjournal.org
Introduction
Significant unprotected left main disease
(ULM) occurs in around 5% of patients with coro-
nary artery disease [1, 2], with significant prognos-
tic and therapeutic implications, as only coronary
revascularization can provide long-term freedom
from myocardial ischemia and is thus recommend-
ed in all suitable patients. Coronary artery bypass
surgery (CABG) has been considered the standard
therapy for patients with unprotected left main coro-
nary disease (ULMD) in recent decades. However,
several studies have demonstrated low in-hospital
complications with elective left main stenting [3, 4].
Reduced periprocedural risks such as the need for
emergency CABG, restenosis, and target lesion
failure with bare metal stents compared to simple
balloon angioplasty and afterwards with drug-elut-
ing stents (DES) have raised the possibility of their
use in more complex lesion subsets such as ULMD.
DESs have been introduced into clinical practice in
the last few years and have proved able to reduce
the risk of restenosis; but the long-term outcome
of these patients remains uncertain [5]. Follow-up
data is particularly important in view of the poten-
tial consequences of either stent thrombosis or res-
tenosis. At present, there is controversy as to
whether these patients can be managed using an
interventional strategy with an efficacy equal to that
of surgery. Thus, the purpose of the present study
was to review a single center experience on left
main stenting. We evaluated procedural outcomes,
techniques used, and clinical and angiographic fol-
low-up.
Methods
Seventy two consecutive (3.9% of the total
volume) stable or unstable (acute coronary syn-
drome — ACS) patients with ULMD treated with
DES from July 2004 to September 2009 at our in-
stitution, were considered for analysis. EuroSCORE
was used in order to identify high preoperative risk
patients with symptomatic left main disease. ULMD
was defined as a greater than 50% stenosis within
the left main coronary artery without distal protec-
tion from previous bypass surgery. According to
lesion location within the left main segment, pa-
tients were classified into groups. In Group A, the
lesion was confined to the ostium or body of the left
main, with at least 5 mm of angiographic insignifi-
cant disease between the distal lesion margin and
the bifurcation. In Group B, the disease involved the
bifurcation of the left main.
The types of stents used were: paclitaxel-elut-
ing Taxus stents (Boston Scientific, Natick, Mas-
sachusetts, USA), sirolimus-eluting Cypher stents
(Cordis, Miami Lakes, Florida, USA), zotarolimus-
-eluting Endeavor stents (Medtronic, Inc. NYSE:
MDT, Minneapolis, Minnesota, USA) and everoli-
mus-eluting Promus stents (Boston Scientific Cor-
poration, Natick, Massachusetts, USA). Stent selec-
tion was based solely on availability or operator
preference. Heparin, bivalirudin or a glycoprotein
IIb/IIIa inhibitor were administered at the discre-
tion of the operator. Prior to the procedure, all pa-
tients were loaded with either 300 or 600 mg clopi-
dogrel and remained on a 75 mg dosage daily for at
least 12 months. Aspirin 100 mg daily was also co-
administered indefinitely.
Deaths were classified as either cardiac or non-
-cardiac. All deaths were considered to be of car-
diac origin unless a clinical diagnosis or an autopsy
proved the origin to be non-cardiac. Myocardial in-
farction (MI) was diagnosed by an elevation of cre-
atine kinase two times the upper limit of normal,
together with an increased MB fraction, in either
the absence or presence of Q-waves. We appraised
the incidence of stroke and heart transplantation,
as well as stent thrombosis according to the Aca-
demic Research Consortium definitions. Function-
ally complete revascularization was defined as com-
plete and successful treatment of all diseased ves-
sels with reference diameter > 2.0 mm, serving
a portion of viable myocardium. Procedural success
was defined as residual stenosis of less than 25%
associated with thrombosis in myocardial infarction
(TIMI) flow grade III without death, MI or emer-
gency bypass surgery prior to hospital discharge.
All patients gave written informed consent before
participation in the study, and the protocol has been
approved by our Institutional Ethics Committee.
Follow-up data was obtained by clinical evalua-
tion at one month, six months, 12 months and sub-
sequently once a year including control angiography
between nine and 12 months, from index procedure.
The study end-points were death, post-procedure
MI, and target vessel revascularization (TVR) in-
cluding target and non-target lesion revasculariza-
tion. MI was defined as a CPK-MB elevation of
three times the upper limit of normal during the
initial hospitalization or follow-up. Stent thrombo-
sis was defined according to established criteria
[16]. Death included both cardiac and non-cardiac
causes. QCA analysis was performed by the expe-
rienced and certified technicians of our cath lab,
using Philips Integris BH 5000 (Philips, Eindhoven,
The Netherlands) with updated software. Continu-
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ous variables were expressed as mean ± standard
deviation of the mean, or as percentages. The Ka-
plan-Meier method was used for survival analysis,
and computations were performed with SPSS 11.0
(SPSS, Chicago, Illinois, USA).
Results
Demographics and clinical presentation of the
study population are shown in Table 1. The mean
age was 70 ± 12 years; 56 (73.6%) patients were
male. Ten (13%) patients were diabetic, and 14
(23.6%) had a previous percutaneous intervention.
The mean ejection fraction was 51.6 ± 13.2. The
mean EuroSCORE was 7.1 ± 4.5 and 47 (65.2%)
patients had a EuroSCORE > 6. One patient had
a diagnosis of cancer at the time of the index pro-
cedure. The most frequent clinical presentations
were unstable angina or non-ST elevation myocar-
dial infarction (NSTEMI), and the next most fre-
quent was stable angina. Procedural characteristics
are shown in Table 2. ULMD was limited to the
ostium or shaft in 32 (44%) patients and involved
predivisional segment or bifurcation in 40 (56%)
patients. Femoral access was utilized in the major-
ity of patients. An intra-aortic balloon pump was uti-
lized in seven (9.7%) patients. Heparin anticoagu-
lation was used in all patients. Glycoprotein IIb/IIIa
inhibitor was used quite frequently in 41 (56.9%)
patients. Procedures were intravascular ultrasound
-guided in 18 (25.8%) patients. Most patients pre-
sented with a three vessel disease associated with
LMD (40 pts, 55.5%). LM lesions were moderately
calcified in 29 (40.0%) patients, eccentric in 42
(58.3%) patients, with TIMI III in the majority of
patients (70 pts, 97.2%) (Table 3). ULMD was treat-
ed with 1.6 ± 1.2 stents per LM for a total of 126
DES. Cutting balloon was required in 18 (25.8%)
patients. A total of 40 bifurcations (including 27 true
bifurcations) was treated using the following tech-
niques: mini crush, 15 (37.5%), T stenting, two (5%)
and provisional stenting, 23 (57.5%). QCA results
are shown in Table 4. Mean reference diameter,
minimal lumen diameter and acute gain were re-
spectively 3.58 ± 0.66 mm, 3.53 ± 0.35 mm and
2.09 ± 0.54 mm. Procedural success was achieved
in all (100%) patients while clinical success occurred
in 70 (96%) patients. Two patients had a NSTEMI
during recovery, while no other complication occurred
in hospital. A clinical evaluation was achieved in all
patients, while an angiographic follow-up was per-
formed on 59 (82%) patients (Table 5). Mean follow-up
Table 1. Clinical characteristics.
Variable 72 pts
Age (years) 70 ± 12
Male 56 (73.6%)
Smoker 17 (23.6%)
Cholesterol 33 (45.8%)
Diabetes 10 (13.8%)
Family history 39 (54%)
Hypertension 39 (54%)
Chronic renal failure 4 (5.5%)
Previous CABG 16 (22%)
Previous PCI 14 (23.6%)
Previous myocardial infarction 25 (34.7%)
History of valve replacement 3 (4%)
LVEF (%) 51.6 ± 13.2
EuroSCORE 7.1 ± 4.5
EuroSCORE > 6 47 (65.2%)
Congestive heart failure 6 (8.3%)
CABG — coronary artery bypass grafting; LVEF — left ventricular
ejection fraction; PCI — percutaneous coronary intervention
Table 3. Angiographic findings.
Variable 72 pts
LM 3 (4.1%)
LM + 1 VD 4 (5.6%)
LM + 2 VD 25 (34.7%)
LM + 3 VD 40 (55.5%)
A 3 (4%)
B 3 (4%)
B2 31 (43.0%)
C 35 (48.6%)
Ca++ 29 (40.0%)
Eccentric 42 (58.3%)
TIMI 3 70 (97.2%)
TIMI 2 1 (1.4%)
TIMI 1 1 (1.4%)
LM — left main; VD — vessel disease; Ca++ — calcification;
TIMI — thrombolysis in myocardial infarction
Table 2. Clinical presentation.
Variable 72 pts
Asymptomatic 2 (2.8%)
Stable angina 17 (23.6%)
Unstable angina and non-STEMI 51 (70.0%)
STEMI 1 (1.4%)
Cardiogenic shock 1 (1.4%)
STEMI — ST elevation myocardial infarction
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Figure 1. Kaplan-Meier analysis depicting event-free
survival.
was 2.5 years ± 10 months. Total major adverse
cardiac events (MACE) occurred in 22 (30.5%) pa-
tients. Overall event-free survival (69.5%) is shown
in Figure 1. During the first 12 months after index
procedure, free of death survival reached 97%,
shaped by two non-cardiac deaths. Overall cardiac
and non-cardiac death occurred in four (5.5%) pa-
tients (Fig. 2). One patient died of throat cancer,
a second patient had a post-traumatic cerebral hem-
orrhage and secondary exitus, and a third died of
progressively deteriorated end stage renal failure.
Finally, a fourth patient died suddenly 24 months
after the index procedure. This was considered as
a possible stent thrombosis. Five (6.9%) patients had
a NSTEMI without further complication (Fig. 3).
Overall TVR, including target lesion revasculariza-
tion, was 14.2%. No CABG was required during fol-
low-up. Furthermore, quantitative coronary angio-
graphic (QCA) analysis during angiographic follow-
up showed no significant variation of MLD (3.36 ±
± 0.63 mm) with a mean late loss of 0.39 ± 0.56 mm.
Discussion
The salient finding of our study is that PCI of
ULMD using DES in patients not eligible for CABG
is a safe and effective option. This message concords
with that of previous large studies [1, 3, 4], indicat-
ing that PCI could be considered as a sound alter-
native to CABG with respect to ULMD, in carefully
selected patients. In fact, there are voices calling for
reconsideration of the current indications regarding
PCI for ULMD with favorable characteristics, possi-
bly altering the standard clinical practice.
Moreover, most clinical follow-up is to date still
limited at the mid-term threshold; thus, results from
randomized trials comparing percutaneous versus
surgical revascularization are still needed to establish
the role of percutaneous DES implantation in the evi-
Figure 2. Kaplan-Meier analysis depicting overall survival.
Table 4. QCA analysis after percutaneous coronary
intervention.
Main Side
vessel  branch
Mean reference 3.58 ± 0.66 2.97 ± 0.50
diameter [mm]
Minimal lumen 3.53 ± 0.35 2.74 ± 0.53
diameter [mm]
Acute gain [mm] 2.09 ± 0.54 0.42 ± 0.71
Stent length [mm] 23.5 ± 18.8 16.4 ± 4.3
Stenosis (%) 9.7 ± 5.5 12.2 ± 4.7
Table 5. QCA analysis at follow-up. Angiographic
follow-up in 59 (82%) patients
Main Side
vessel  branch
Mean reference 3.38 ± 0.66 2.64 ± 0.58
diameter [mm]
Minimal lumen 3.36 ± 0.63 2.30 ± 0.54
diameter [mm]
Stenosis (%) 19.4 ± 11.7 34.2 ± 23.0
Late loss [mm] 0.39 ± 0.56 0.44 ± 0.58
Restenosis 5 (6.9%) 10 (13.8%)
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dence-based medicine hierarchy, in comparison with
the reference treatment, i.e. surgery, especially gi-
ven recent concerns about late stent thrombosis.
ULMD is present in 5% of patients undergo-
ing coronary angiography [6] and has been, for de-
cades, a strict indication for CABG. Since DES ap-
proval [5], their use has been not only limited in
patients with ULM at very high surgical risk, but
also expanded in those with more favorable lesion
characteristics [7]. Although most reports repre-
sented small, single-center experiences, with ob-
vious limitations in external validity, the available
evidence on patient selection and risk stratification
in patients undergoing PCI with DES for ULM has
already established that non-bifurcational ULMD is
associated with a more favorable prognosis than
distal ULM. However, whether surgery should be
the first-line treatment even for non-bifurcational
ULMD remains a topic for debate [8]. Recent stud-
ies have led to an overall reappraisal of the long-
-term safety of DES [9] given the likely increase in
stent thrombosis, and this has had even greater
implications on DES-based PCI for ULM. The ben-
eficial impact of DES over BMS in these lesions is
clearly shown in the available controlled studies.
Indeed, in-stent restenosis has been called into
question as a potential cause of acute coronary syn-
dromes in unspecified lesions, but in ULM resteno-
sis, it is recognized as a potential cause of sudden
cardiac death or MI. Thus, the antiproliferative ac-
tion of DES is of paramount importance in ULM
lesions, and to date, DES should probably be re-
commended whenever PCI for ULMD is planned.
This is a single-center study regarding ULMD
stenting. Events were both cardiac and secondary
to comorbid conditions in these patients with in-
creased surgical risk. The 4% incidence of in-hos-
pital complications with two NSTEMI is consistent
with other reports demonstrating that ULM stent-
ing can be performed with few periprocedural com-
plications [10–18]. However, there was a substan-
tial incidence of late adverse events in the present
study, and overall event-free survival was 70% at
a mean period of 2.5 years. Overall mortality at
30 months was 6.1% with three non-cardiac deaths. No
definite or probable stent thrombosis was docu-
mented. It should be emphasized that the study
population did have increased surgical risk. Sixty-
-two percent had a EuroSCORE > 6, which corre-
sponds to an expected 30-day operative mortality
of between 10% and 12%, and the mean Euro-
SCORE was 7.1 ± 4.5 for the entire cohort [19, 20].
Surgical risk was increased primarily due to comor-
bid conditions, as opposed to left ventricular dys-
function, since resting mean ejection fraction was
51.6 ± 13.2%. Thus, the overall event-free survival
was at least in part caused by comorbid conditions.
The final results of this study will ultimately be ne-
cessary to answer questions regarding the efficacy
of left main stenting. In the meantime, most experts
recommend a cautious approach. ULMD remains
a Class I indication for CABG, and stenting should
be performed only in patients with definitely in-
creased surgical risk, or serious comorbid illness-
es limiting life expectancy [21]. The most impor-
tant limitation of the present study is that it is
a single-center, retrospective, observational work,
performed on a somewhat selected population.
Thus, the results and conclusions must be inter-
preted with caution, and not generalized from.
Conclusions
Despite a high in-hospital procedural success
rate with ULM stenting using DES, a substantial
number of adverse events occurred during the fol-
low-up period in our study. Events occurred with
greater frequency in bifurcation groups as compared
to ostial or mid-shaft lesions. Pending definitive data
from randomized ULMD trials in broader cohorts,
ULM stenting should be reserved for patients who
are not appropriate surgical candidates.
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